RGNX Stock REGENXBIO (RGNX, $13.39) was a top quarterly gainer, rising +49.94%

GET DAILY SIGNALS

Get AI intraday signals

RGNX - REGENXBIO

Loading...

Price: $13.39

Daily change: +$0.13 (+0.98%)

Daily volume: 1.1M

3-month price change: +$4.46 (+49.94%)

Capitalization: $677.8M

Industry: Biotechnology

REGENXBIO (RGNX, $13.39) was one of top quarterly gainers, jumping +4 to $13.39 per share. A.I.dvisor analyzed 759 stocks in the Biotechnology Industry over the last three months, and discovered that of them (7) charted an Uptrend while of them (2) trended down.

RGNX's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for RGNX moved out of overbought territory on November 26, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RGNX broke above its upper Bollinger Band on November 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RGNX entered a downward trend on November 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 21, 2025. You may want to consider a long position or call options on RGNX as a result. In of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RGNX just turned positive on November 25, 2025. Looking at past instances where RGNX's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

RGNX moved above its 50-day moving average on November 21, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNX advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.951) is normal, around the industry mean (27.312). P/E Ratio (0.000) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (4.011) is also within normal values, averaging (321.020).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.